

**SITC**  
2017

## **SITC 2017 Downloadable Schedule**

### **Pre-Conference Programs • Nov. 8-9**

#### **Immuno-Oncology Biomarkers: Today's Imperatives for Tomorrow's Needs**

Nov. 8, 2017

#### **2<sup>nd</sup> World Immunotherapy Council Young Investigator Symposium**

Nov. 8, 2017

#### **Primer on Tumor Immunology and Cancer Immunotherapy™**

Nov. 9, 2017

#### **Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy**

Nov. 9, 2017

#### **Meet-the-Expert Lunch**

Nov. 9, 2017

#### **Grant Writing Workshop**

Nov. 9, 2017

### **32<sup>nd</sup> Annual Meeting • Nov. 10-12**



Society for Immunotherapy of Cancer

**#SITC2017**

# Immuno-Oncology Biomarkers: Today's Imperatives for Tomorrow's Needs

Wednesday, November 8, 2017

*Cherry Blossom Ballroom*

8 – 8:15 a.m.                      **Welcome and Introductions**  
Lisa H. Butterfield, PhD – *University of Pittsburgh*

## Session I: Biomarkers in Development

### General Biomarkers

8:15 – 8:25 a.m.                      **Immune Report Card**  
Carl Morrison, MD, DVM – *OmniSeq, Inc.*

8:25 – 8:35 a.m.                      **Multiplex IHC Immuno-Oncology Panel for Standardized Profiling of the Immune Status Based on Spatial and Functional Characterization of the Tumor Microenvironment**  
Svenja Lippok, PhD – *Definiens AG*

8:35 – 8:45 a.m.                      **Exosome Repertoires and Cargo Associated with Tumor Progression and Responses to Treatment**  
Jennifer Jones, MD, PhD – *National Institutes of Health, National Cancer Institute, Center for Cancer Research*

8:45 – 8:55 a.m.                      **A Biomarker-Driven Approach for the Development of the ICOS Agonist Antibody, JTX-2011**  
Heather A. Hirsch, PhD – *Jounce Therapeutics, Inc.*

8:55 – 9:10 a.m.                      **Group Discussion**

### Biomarkers Supporting Primarily Immune Checkpoint Blockade

9:10 – 9:20 a.m.                      **Composite Predictors of Efficacy to Checkpoint Inhibitors and Mechanisms of Immune Escape, Informing Combination Strategies via Personalized Cancer Immunotherapy**  
Priti S. Hedge, PhD – *Genentech*

9:20 – 9:30 a.m.                      **Pretreatment Gene Expression Correlation with Clinical Response to Pembrolizumab or Nivolumab in Metastatic Melanoma**  
Tobias Scatton, PharmD, PhD – *Harvard Medical School & Brigham and Women's Hospital*

9:30 – 9:40 a.m.                      **Calibration of FoundationOne® with Whole Exome Sequencing for Assessment of Tumor Mutation Burden as a Biomarker for Response to Immune Checkpoint Inhibitors**  
Joseph D. Szustakowski, PhD – *Bristol-Meyers Squibb*

9:40 – 9:50 a.m.                      **Biomarkers for Primary Immunotherapy Resistance Based on the Circulating Proteome**  
Heinrich Roder, PhD – *Biodesix Inc.*

9:50 – 10:05 a.m.                      **Group Discussion**

10:05 – 10:20 a.m.                      **Break**

## **Biomarkers Supporting Primarily T cell Interventions**

- |                      |  |
|----------------------|--|
| 10:20 – 10:30 a.m.   | <b>Pharmacodynamic and Predictive Biomarkers Supporting Development of CAR T Cells for the Treatment of B cell Malignancies</b><br>John Rossi, MSc – <i>Kite Pharma, Inc.</i>          |
| 10:30 – 10:40 a.m.   | <b>Single T cell Functional Response Biomarkers to Differentiate Responders and Non-Responders in CAR-T and Checkpoint Based cancer Immunotherapies</b><br>Jon Chen – <i>Isoplexis</i> |
| 10:40 – 10:50 a.m.   | <b>Standardized Immune-Based Diagnostic Tests to Predict the Risk of Recurrence and Response to Therapy of Cancer Patients</b><br>Fabienne Hermitte, PhD – <i>HalioDx</i>              |
| 10:50 – 11 a.m.      | <b>Public NY-ESO-1 Specific TCRs as Novel Biomarkers for Immune Monitoring of NY-ESO-1 Positive Cancer Patients</b><br>Hailing Lu, MD, PhD – <i>Immune Design</i>                      |
| 11 a.m. – 11:15 a.m. | <b>Group Discussion</b>  |
| 11:15 – 11:30 a.m.   | <b>Break</b>   |

## **Session II: Strategic Considerations of Biomarkers**

- |                    |   |
|--------------------|---|
| 11:30 – 11:45 a.m. | <b>The Regulatory Perspective</b><br>Gideon Blumenthal, MD – <i>Food &amp; Drug Administration</i>  |
| 11:45 – 12:25 p.m. | <b>Panel Discussion</b><br>Jerome Galon, PhD – <i>INSERM- Cordeliers Research Center</i><br>Francesco Marincola, MD – <i>AbbVie Inc.</i><br>Minkyung Song, PhD – <i>National Cancer Institute, National Institute of Health</i> |
| 12:25 – 12:30 p.m. | <b>Closing Remarks</b>  |
| 7 – 8 p.m.         | <b>Networking Reception</b><br><i>Cherry Blossom Foyer</i>  |

## 2<sup>nd</sup> World Immunotherapy Council Young Investigator Symposium

**Wednesday, November 8, 2017**

*Cherry Blossom Ballroom*

1 – 1:05 p.m.

**Welcome and Introductions**

Tanja de Gruijl, PhD – *VU University Medical Center*

Graham Pawelec, PhD – *University of Tuebingen*

**Session I: Checkpoint Blockade**

*Senior Co-Chairs:*

Beatrix Kotlan, PhD – *National Institute of Oncology, Budapest*

Sacha Gnjatic, PhD – *Cancer Research Institute (CRI)*

Zihai Li, MD, PhD – *Chinese American Hematology Oncology Network (CAHON)*

Lisa H. Butterfield, PhD – *Society for Immunotherapy of Cancer (SITC)*

Willemijn Hobo, PhD – *Dutch Tumor Immunology Working Party (DTIWP)*

1:05 – 1:10 p.m.

**Junior Co-Chair Welcome**

Hong Zheng, MD, PhD – *Pennsylvania State Cancer Institute*

1:10 – 1:25 p.m.

**Immunotherapy - Long-Term Survival in Metastatic Melanoma**

Katalin Czirbesz, MD – *National Institute of Oncology, Budapest*

1:25 – 1:40 p.m.

**PD-1 Blockade: Understanding CD8 T Cell Rescue for Insights into Cancer Immunotherapy**

Alice O. Kamphorst, PhD – *Cancer Research Institute (CRI)*

1:40 – 1:55 p.m.

**Viral Based Cancer Immunotherapy in the Era of Immune Checkpoint Blockade**

Liang Deng, MD, PhD – *Chinese American Hematology Oncology Network (CAHON)*

1:55 – 2:10 p.m.

**Treg Modulation as a Pharmacodynamic Biomarker of GITR Stimulation in Cancer Patients**

Roberta Zappasodi, PhD – *Society for Immunotherapy of Cancer (SITC)*

2:10 – 2:25 p.m.

**PD-L1 Expression on Malignant Cells is no Prerequisite for Checkpoint Therapy**

Jan Willem Kleinovink, MS – *Dutch Tumor Immunology Working Party (DTIWP)*

2:25 – 2:40 p.m.

**Break**

**Session II: Adoptive T Cell Therapy**

*Senior Co-Chairs:*

Robert E. Hawkins, MD, PhD – *Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)*

Per thor Straten, PhD – *Progress in Vaccination Against Cancer (PIVAC)*

Pamela Ohashi, PhD – *Canadian Cancer Immunotherapy Consortium (CCIC)*

2:40 – 2:45 p.m.

**Junior Co-Chair Welcome**

Marco Ruella, MD – *University of Pennsylvania*

2:45 – 3:00 p.m.

**Exploiting Tumor Infiltrating Lymphocytes (TILs) as a Therapeutic Strategy for Epithelial Ovarian Cancer**

Gemma Owens, MB, BCh – *Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)*

3:00 – 3:15 p.m. **Combined Killing of Cancer Cells and Cross Presentation of Tumor Antigens By V $\gamma$ 9V $\delta$ 2 T Cells**  
Gitte Holmen Olofsson, MS – *Progress in Vaccination Against Cancer (PIVAC)*

3:15 – 3:30 p.m. **A Novel Innate Lymphoid Cell Population Regulates Tumor – Associated T Cells**  
Sarah Crome, PhD – *Canadian Cancer Immunotherapy Consortium (CCIC)*

3:30 – 3:45 p.m. **Break**

### Session III: Innate Immunity

#### Senior Co-Chairs:

Weihua Xiao, MD, MS – *Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio Therapy (TIBT)*

Heinz Zwiertzina, MD – *Cancer Drug Development Forum (CDDF)*

Angus Dalgleish, MD, PhD – *Institute for Cancer Vaccines and Immunotherapy (ICVI)*

3:45 – 3:50 p.m. **Junior Co-Chair Welcome**  
Cheng Sun, MD, PhD – *Chinese Academy of Sciences and University of Science & Technology of China*

3:50 – 4:05 p.m. **Dysfunction of Dendritic Cells in Lung Cancer**  
Fang Fang, PhD – *Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)*

4:05 – 4:20 p.m. **Development of a Novel Immunotherapy with Toll-Like and Nod-Like Receptors Synergy for Targeted Cancer Therapy**  
Célia Jacobberger-Foissac, MSc – *Cancer Drug Development Forum (CDDF)*

4:20 – 4:35 p.m. **Zoledronic Acid Induces Gamma Delta T Cells to Target Macrophages**  
Daniel William Fowler, PhD – *Institute for Cancer Vaccines and Immunotherapy (ICVI)*

4:35 – 5:40 p.m. **Dinner Break**

### Session IV: Novel Approaches to Improve Immunotherapy

#### Senior Co-Chairs:

Kazuhiro Kakimi, MD, PhD – *Japanese Association of Cancer Immunology (JACI)*

Barbara Seliger, MD, PhD – *Tumor Immunology Meets Oncology (TIMO)*

Michele Maio, MD, PhD – *NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)*

Giuseppe Masucci, MD, PhD – *Scandinavian Network for Immunotherapy of Cancer (SNIC)*

5:40 – 5:45 p.m. **Junior Co-Chair Welcome**  
Margot Pont, PhD – *Fred Hutchinson Cancer Research Center*

5:45 – 6:00 p.m. **An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Cancer Immunotherapy**  
Takahiro Karasaki, MD – *Japanese Association of Cancer Immunology (JACI)*

6:00 – 6:15 p.m. **Reversing the Tumor Immune Escape with Selenium**  
Claudia Lennicke, PhD – *Tumor Immunology Meets Oncology (TIMO)*

6:15 – 6:30 p.m. **Epigenetic Immunomodelling to Improve the Efficacy of Cancer Immunotherapy**  
Alessia Covre, PhD – *NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)*

6:30 – 6:45 p.m. **Blood in Circulation, with Intact Cascade Systems, as a Tool to Predict First-Infusion Reactions and Mechanism of - Action of Immunotherapeutics**  
Erika Fletcher, PhD – *Scandinavian Network for Immunotherapy of Cancer (SNIC)*

6:45 – 7 p.m.

**Closing Remarks**

Graham Pawelec, PhD – *University of Tuebingen*

7 – 8 p.m.

**Networking Reception**

*Cherry Blossom Foyer*

# Primer on Tumor Immunology and Cancer Immunotherapy™

**Thursday, November 9, 2017**

*Maryland Ballroom C*

8 – 8:05 a.m.                    **Welcome and Introductions**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai*

## **Session I: Basic Immunology – A Brief Overview**

8:05 – 8:35 a.m.                    **Innate Lymphocytes**  
Amir Horowitz, PhD – *Icahn School of Medicine at Mount Sinai*

8:35 – 9:05 a.m.                    **Monocytes and Macrophages in Cancer**  
Vincenzo Bronte, MD – *University of Verona*

9:05 – 9:35 a.m.                    **Dendritic Cells and Antigen**  
A. Karolina Palucka, MD, PhD – *The Jackson Laboratory for Genomic Medicine*

9:35 – 10:05 a.m.                    **Adaptive Immunity**  
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

10:05 – 10:20 a.m.                    **Panel Questions and Answers**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai*

10:20 – 10:35 a.m.                    **Break**

## **Session II: Treating Tumors with Passive Immunotherapy**

10:35 – 10:40 a.m.                    **Session II Introduction**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai*

10:40 – 11:10 a.m.                    **Cytokines: Interferons, Interleukins and Beyond**  
Jeffrey S. Miller, MD – *University of Minnesota*

11:10 – 11:40 a.m.                    **Adoptive T Cell Therapy**  
Cassian Yee, MD – *University of Texas MD Anderson Cancer Center*

11:40 – 12:10 p.m.                    **Monoclonal Antibodies and Bi-Specifics/Structure and Mechanism of Action**  
Charles G. Drake, MD, PhD – *Columbia University Medical Center*

12:10 – 12:25 p.m.                    **Panel Questions and Answers**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Mount Sinai Medical Center*

12:30 – 1:30 p.m.                    **Lunch**

## **Session III: Active Immunotherapy: Unleashing the Patient's Own Immune System**

1:30 – 1:35 p.m.                    **Session III Introduction**  
Timothy NJ Bullock, PhD – *University of Virginia*



1:35 – 2:05 p.m.      **Targeting Regulatory Molecules in Cancer Therapy: New Insights and Opportunities**  
Michael A. Curran, PhD – *University of Texas MD Anderson Cancer Center*

2:05 – 2:35 p.m.      **Cancer Vaccines**  
Ross Kedl, PhD – *University of Colorado School of Medicine*

2:35 – 2:50 p.m.      **Panel Questions and Answers**  
Timothy NJ Bullock, PhD – *University of Virginia*

2:50 – 3:05 p.m.      **Break**

#### **Session IV: Immune Monitoring: Figuring Out How it All Works**

3:05 – 3:10 p.m.      **Session IV Introduction**  
Timothy NJ Bullock, PhD – *University of Virginia*

3:10 – 3:40 p.m.      **Immune Monitoring and Next Generation**  
Sacha Gnajatic, PhD – *Icahn School of Medicine at Mount Sinai*

3:40 – 4:10 p.m.      **On The Horizon: IO Combinations**  
Jeffrey Sosman, MD – *Northwestern University*

4:10 – 4:40 p.m.      **Biomarkers – Mutational Load**  
Timothy A. Chan, MD, PhD – *Memorial Sloan Kettering Cancer Center*

4:40 – 4:55 p.m.      **Panel Questions and Answers**  
Timothy NJ Bullock, PhD – *University of Virginia*

4:55 – 5 p.m.      **Closing Remarks**  
Timothy NJ Bullock, PhD – *University of Virginia*



# Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy

**Thursday, November 9, 2017**

*Maryland Ballroom A*

8 – 8:05 a.m.                    **Welcome and Introductions**  
Nicholas McGranahan, PhD – *University College London*

## **Session I: Tumor Heterogeneity and Evolution under Immune Pressure and Treatment**

*Chair: Nicholas McGranahan, PhD – University College London*

8:05 – 8:30 a.m.                **T Cell Plasticity and Cancer Immunoediting**  
Charles Swanton, MD, PhD, FRCP – *University College London*

8:30 – 8:55 a.m.                **Tumor Neoantigens and Presentation and Recognition**  
James R. Heath, PhD – *California Institute of Technology*

8:55 – 9:20 a.m.                **Evolution of Neoantigen Landscapes**  
Valasmo Anagnostou, MD, PhD – *Johns Hopkins University*

9:20 – 9:45 a.m.                **Break**

## **Session II: Tumor Immune Microenvironment**

*Chair: Gordon J. Freeman, PhD – Dana Farber Cancer Institute*

9:45 – 10:10 a.m.                **T cell Differentiation in the Tumor Microenvironment**  
Ana C. Anderson, PhD – *Harvard Medical School*

10:10 – 10:35 a.m.                **Analysis of Human Anti-Tumor Immune Responses**  
Nir Hacohen, PhD – *Massachusetts General Hospital*

10:35 – 11 a.m.                    **Myeloid Cells in Lung Tumors Using CyTOF**  
Miriam Merad, MD, PhD – *Icahn School of Medicine at Mount Sinai*

11 – 11:25 p.m.                    **Computational Methods for Analyzing Single Cells in the Tumor Microenvironment**  
Dana Pe'er, PhD – *Memorial Sloan Kettering Cancer Center*

11:25 – 11:50 a.m.                **Methods and Applications of Single Cell Genomics**  
Rahul Satija, PhD – *New York Genome Center*

11:50 a.m. – 12:15 p.m.            **Mass Spectrometry and Basic Spatial Imaging Methods of Tissues**  
Michael Angelo, MD, PhD – *Stanford University*

12:15 – 1 p.m.                    **Lunch**

## **Session III: Predictor Response & Liquid Biopsy**

*Chair: Gordon J. Freeman, PhD – Dana Farber Cancer Institute*

1 – 1:25 p.m.                    **PDL1 Response**  
Priti Hegde, PhD – *Genentech*

1:25 – 1:50 p.m.                **Pre & Post PD1**  
Sean Mackay – *IsoPlexis*

1:50 – 2:15 p.m.      **Analysis of Circulating Tumor DNA/Tumor Cells**  
Abhijit Patel, MD, PhD – Yale University School of Medicine

2:15 – 2:40 p.m.      **Influence of Gut Microbiome upon PD1/I-O Responses**  
Jennifer A. Wargo, MD, MMSc – *University of Texas MD Anderson Cancer Center*

2:40 – 3:05 p.m.      **Break**

**Session IV: How to Apply Single Cell to Your Research**

*Chair: Nir Hacohen, PhD – Massachusetts General Hospital*

3:05 – 4:05 p.m.      **Discussion on Experimental and Computational Methods**  
Alexandra-Chloé Villani, PhD – *Broad Institute of Massachusetts Institute of Technology*

4:05 – 4:55 p.m.      **Panel Discussion**  
Nir Hacohen, PhD – *Massachusetts General Hospital*

4:55 – 5 p.m.      **Closing Remarks**  
Nir Hacohen, PhD – *Massachusetts General Hospital*

## Meet-the-Expert Lunch

Thursday, November 9, 2017

*Chesapeake JKL*

12:30 – 12:35 p.m.	<b>Welcome</b> Davide Bedognetti, MD, PhD – <i>Sidra Medical and Research Center</i>
12:35 – 1:20 p.m.	<b>Publishing Papers</b> Susan Kaech, PhD – <i>Yale University</i>
12:35 – 1:20 p.m.	<b>Networking and Developing Successful Collaborations</b> Jennifer Wargo, MD, MMSC – <i>University of Texas MD Anderson Cancer Center</i>
12:35 – 1:20 p.m.	<b>Basic-Translational Research</b> Nir Hacohen, PhD – <i>Massachusetts General Hospital</i>
12:35 – 1:20 p.m.	<b>Clinical-Translational Research</b> Mario Sznol, MD – <i>Yale Cancer Center</i>
12:35 – 1:20 p.m.	<b>Career Path: Alternative Careers – Science Policy, Funding Advocacy and Project Management</b> Howard L. Kaufman, MD, FACS – <i>Replimune Group, Inc.</i>
12:35 – 1:20 p.m.	<b>Career Path: The Big Pharma Industry Perspective</b> Kimberly Shafer-Weaver – <i>AstraZeneca, LP</i>
12:35 – 1:20 p.m.	<b>Career Path: The Small Biotech Industry Perspective</b> Alessandra Cesano, MD, PhD – <i>NanoString Inc.</i>
12:35 – 1:20 p.m.	<b>Career Path: How to Kick-Start Your Career in the US – An International Perspective</b> Sandra Demaria, MD – <i>Weill Cornell Medical College</i>
12:35 – 1:20 p.m.	<b>Career Path: How to Survive in Academia</b> Jonathan Powell, MD, PhD – <i>Johns Hopkins University School of Medicine</i>
12:35 – 1:20 p.m.	<b>Career Path: How to Navigate the Postdoc to PI Transition</b> Matthew Gubin – <i>Washington University School of Medicine</i>
1:20 – 1:30 p.m.	<b>Networking Time</b>

# Grant Writing Workshop

## Thursday, November 9, 2017

### Session I: Introduction to Grant Writing

*Chesapeake DE*

- |                  |   |
|------------------|---|
| 1:30 – 1:35 p.m. | <b>Welcome and Overview of Grant Writing Workshop</b><br>Lorenzo Falchi, MD – <i>Columbia University Medical Center</i> |
| 1:35 – 1:40 p.m. | <b>Introductions</b><br>Marco Ruella, MD – <i>University of Pennsylvania</i>  |
| 1:40 – 2:05 p.m. | <b>Identifying and Selecting the Right Grant</b><br>Sandra Demaria, MD – <i>Weill Cornell Medical College</i>           |
| 2:05 – 2:30 p.m. | <b>Mechanics of Grant Writing</b><br>John Barrett, MD – <i>National Heart, Lung, and Blood Institute</i>                |
| 2:30 – 2:45 p.m. | <b>Panel Discussion</b>   |
| 2:45 – 3 p.m.    | <b>Break</b>  |

### Session II: Mechanisms of Grant Review

#### Track A: Career Development Awards

*Chesapeake DE*

- |                  |  |
|------------------|--|
| 3 – 3:05 p.m.    | <b>Welcome and Introductions</b><br>Jennifer Guerriero, PhD – <i>Dana-Farber Cancer Institute</i>          |
| 3:05 – 3:35 p.m. | <b>Overview of Awards from Foundations and Societies</b><br>Kim A. Margolin, MD – <i>City of Hope</i>      |
| 3:35 – 4:05 p.m. | <b>Overview of NIH Transition Grants</b><br>Sonia Jakowlew, PhD – <i>National Institutes of Health</i>     |
| 4:05 – 4:20 p.m. | <b>Break</b>   |
| 4:20 – 5 p.m.    | <b>Guided Tour of NIH Peer Review Process</b><br>Sergei Radaev, PhD – <i>National Institutes of Health</i> |
| 5 – 5:25 p.m.    | <b>Panel Discussion</b>  |
| 5:25 – 5:30 p.m. | <b>Closing Remarks</b><br>Jennifer Guerriero, PhD – <i>Dana-Farber Cancer Institute</i>                    |

#### Track B: Nonprofit or Government Grants for Independent Investigators

*Chesapeake H*

- |               |   |
|---------------|---|
| 3 – 3:05 p.m. | <b>Welcome and Introductions</b><br>Ana Carrizosa Anderson, PhD – <i>Harvard Medical School</i> |
|---------------|---|

3:05 – 3:35 p.m.	<b>Overview of Non-Profit Sector Funding</b> William H. Chambers, PhD – <i>American Cancer Society</i>
3:35 – 4:05 p.m.	<b>Overview of NIH/NCI Grants</b> Susan McCarthy, PhD – <i>National Cancer Institutes, Division of Cancer Biology</i>
4:05 – 4:20 p.m.	<b>Break</b>
4:20 – 5 p.m.	<b>Guided Tour of NIH Peer Review Process</b> Denise R. Shaw, PhD – <i>National Institutes of Health, Center for Scientific Review</i>
5 – 5:25 p.m.	<b>Panel Discussion</b>
5:25 – 5:30 p.m.	<b>Closing Remarks</b> Ana Carrizosa Anderson, PhD – <i>Harvard Medical School</i>

## 32<sup>nd</sup> Annual Meeting

### Friday, November 10, 2017

- 7 a.m. – 8 a.m.                      **Breakfast**  
*Maryland and Cherry Blossom Foyers*
- 7 a.m. – 6:30 p.m.                **Registration**  
*Cherry Blossom Foyer*
- 8 – 8:05 a.m.                      **Presidential Welcome**  
Lisa H. Butterfield, PhD – *University of Pittsburgh*

#### Update Session

##### **Session 100: National Cancer Institute Update** *Maryland Ballroom*

- 8:05 – 8:20 a.m.                      **National Cancer Institute Update**  
T. Kevan Howcroft, PhD – *National Cancer Institute*
- 8:20 – 8:35 a.m.                      **2016 NCI Immunotherapy Fellowship Update**  
Julius Strauss, MD – *National Cancer Institute*

#### Plenary Session

##### **Session 101: Keynote Address: The CAR T Revolution in Leukemia** *Maryland Ballroom*

- 8:35 – 8:40 a.m.                      **Welcome and Introductions**  
Lisa H. Butterfield, PhD – *University of Pittsburgh*
- 8:40 – 9:20 a.m.                      **The CAR T Revolution in Leukemia**  
Stephan Grupp, MD, PhD – *University of Pennsylvania*
- 9:20 – 9:25 a.m.                      **Q&A and Closing Remarks**  
Stephan Grupp, MD, PhD – *University of Pennsylvania*

#### Plenary Session

##### **Session 102: Science Behind the Therapy: Mechanisms of Efficacy & Toxicity** *Maryland Ballroom*

###### *Co-Chairs:*

Kevan Herold, MD – *Yale University*  
Arlene H. Sharpe, MD, PhD – *Harvard Medical School*

- 9:25 – 9:35 a.m.                      **Introduction**  
Arlene H. Sharpe, MD, PhD – *Harvard Medical School*
- 9:35 – 9:55 a.m.                      **Clinical Overview of Checkpoint Inhibitors**  
Jeffrey A. Sosman, MD – *Northwestern University*
- 9:55 – 10:15 a.m.                      **Autoimmune Endocrinopathies**  
Kevan Herold, MD – *Yale University*
- 10:15 – 10:30 a.m.                      **Break**  
*Maryland Foyers*

- 10:30 – 10:50 a.m.      **Colitis**  
Michael Dougan, MD, PhD – *Massachusetts General Hospital*
- 10:50 – 11:10 a.m.      **Cardiovascular Autoimmunity**  
Andrew Lichtman, MD, PhD – *Brigham and Women's Hospital*
- 11:10 – 11:30 a.m.      **Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analyses of Patient, Protocol and Product Attributes**  
Mark J. Gilbert, MD – *Juno Therapeutics, Inc.*
- 11:30 – 11:45 a.m.      **Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis**  
Jennifer Wu, PhD – *Northwestern University*
- 11:45 a.m. – Noon      **Diversity and Composition of the Gut Microbiome Influences Responses to Anti-PD1-Therapy through Beneficial Changes in Innate and Adaptive Immunity**  
Vancheswaran Gopalakrishnan, PhD – *The University of Texas MD Anderson Cancer Center*

#### Late-Breaking Abstract Session I

##### Session 103: Oral Abstract Presentations

*Maryland Ballroom*

- Noon – 12:15 p.m.      **Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies**  
Thomas S. Uldrick, MD, MD – *National Cancer Institute*
- 12:15 – 12:30 p.m.      **Nivolumab in Mismatch-Repair Deficient (MMR-d) Cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D Preliminary Results**  
Nilofer Azad, MD – *Johns Hopkins University*
- 12:30 – 2 p.m.      **Lunch, Poster Viewing\*, Exhibits**  
*Prince George's Exhibition Hall DE*  
*\*Odd Poster Number Authors Present*
- 12:45 – 1:45 p.m.      **Oral Poster Sessions**  
*Back of Prince George's Exhibition Hall DE*

#### Concurrent Sessions

##### Concurrent Session 104: Clinical Trials: New Agents

*Maryland Ballroom*

- 1:45 – 2 p.m.      **First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors**  
Robert Vonderheide, MD, PhD – *Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania*
- 2 – 2:15 p.m.      **First-in-Human Study with Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results with ADC-1013/JNJ-64457107 in Advanced Solid Malignancies**  
Peter Ellmark, PhD – *Alligator Bioscience*



- 2:15 – 2:30 p.m.      **Monotherapy Dose Escalation Clinical and Translational Data from First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective, PI3K-Gamma Inhibitor Targeting Tumor Macrophages**  
David Hong, MD – *University of Texas MD Anderson Cancer Center*
- 2:30 – 2:45 p.m.      **Phase 1 Trial of CA-170, a First-in-Class, Orally Available, Small Molecule Immune Checkpoint Inhibitor (ICI) Dually Targeting PD-L1 and VISTA, in Patients with Advanced Solid Tumors or Lymphomas**  
Yung Jue Bang, PhD, MD – *Seoul National University Hospital*
- 2:45 – 3 p.m.      **Phase I Trial of IL-15 Superagonist ALT-803 (IL-15N72D:IL-15R $\alpha$ Su/IgG1 Fc complex) in Advanced Solid Tumors: Tolerability and Correlates of Activity**  
Kim Margolin, MD, FACP – *City of Hope*
- 3 – 3:15 p.m.      **Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF- $\beta$ , in Patients with NSCLC Refractory or Resistant to Prior Anti-PD-1/Anti-PD-L1 Agents**  
James L. Gulley, MD, PhD, FACP – *National Cancer Institute*
- 3:15 – 3:30 p.m.      **Phase I Study of E7046, a Novel PGE2 Receptor Type 4 Inhibitor, in Patients with Advanced Solid Tumors with High Myeloid Infiltrate: Effects on Myeloid- and T-Lymphoid Cell-Mediated Immunosuppression**  
Aurelien Marabelle, MD, PhD – *Gustave Roussy Institute*

**Concurrent Session 105: Building Personalized Vaccines and Technologies for Hematologic Malignancies and Solid Tumors**

*Cherry Blossom Ballroom*

*Co-Chairs:*

Matthew M. Gubin, PhD – *Washington University School of Medicine*

Catherine J. Wu, MD – *Dana-Farber Cancer Institute*

- 2 – 2:05 p.m.      **Introduction**  
Matthew M. Gubin, PhD – *Washington University School of Medicine*
- 2:05 – 2:25 p.m.      **Preclinical & Mouse Models**  
Matthew M. Gubin, PhD – *Washington University School of Medicine*
- 2:25 – 2:45 p.m.      **Tumor Vaccines in AML**  
David E. Avigan, MD – *Beth Israel Deaconess Medical Center*
- 2:45 – 3:05 p.m.      **Improvement in Epitope Discovery**  
Catherine J. Wu, MD – *Dana-Farber Cancer Institute*
- 3:05 – 3:20 p.m.      **Predictive Biomarkers for Response to Anti-CTLA-4 and Anti-PD-1 Immunotherapy in Melanoma Patients**  
Priyanka Subrahmanyam, PhD – *Stanford University*

**Plenary Session**

**Session 106: High Impact Clinical Trial Results**

*Maryland Ballroom*

*Chair: Mario Sznol, MD – Yale School of Medicine*

- 3:30 – 3:35 p.m.      **Introduction**  
Mario Sznol, MD – *Yale School of Medicine*
- 3:35 – 3:50 p.m.      **Pooled 3-Year Overall Survival Data from Phase II and Phase III Trials of Nivolumab (NIVO) Combined with Ipilimumab (IPI) in Advanced Melanoma**  
F. Stephen Hodi, MD – *Dana-Farber Cancer Institute*

- 3:50 – 4:05 p.m.      **Nivolumab + Ipilimumab (N+I) vs Sunitinib (S) for Treatment-Naïve Advanced or Metastatic Renal Cell Carcinoma (aRCC): Results From CheckMate 214, including Overall Survival by Subgroups**  
Robert J. Motzer, MD – *Memorial Sloan Kettering Cancer Center*
- 4:05 – 4:20 p.m.      **Immune and Tumor Responses to Human IL-10 (AM0010, Pegilodecakin) Alone or in Combination with Immune Checkpoint Blockade**  
Martin Oft, MD – *ARMO BioScience*
- 4:20 – 4:35 p.m.      **A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors**  
Glen J. Weiss, MD – *Western Regional Medical Center Inc.*
- 4:35 – 4:50 p.m.      **Expert Discussant**  
Samir N. Khleif, MD – *Georgia Cancer Center*
- 4:50 – 5:05 p.m.      **Break**  
*Prince George's Exhibition Hall DE*

#### Concurrent Sessions

##### **Concurrent Session 107: Oncolytic Viruses and Intratumoral Therapies**

*Cherry Blossom Ballroom*

*Co-Chairs:*

Howard L. Kaufman, MD, FACS – *Replimune Group Inc.*

Samuel Rabkin, PhD – *Massachusetts General Hospital*

- 5:05 – 5:10 p.m.      **Introduction**  
Howard L. Kaufman, MD, FACS – *Replimune Group Inc.*
- 5:10 – 5:30 p.m.      **Oncolytic Viruses in Combination Immunotherapy Approaches**  
Howard L. Kaufman, MD, FACS – *Replimune Group Inc.*
- 5:30 – 5:50 p.m.      **Oncolytic Herpes Simplex Virus Immunovirotherapy for Glioblastoma**  
Samuel Rabkin, PhD – *Massachusetts General Hospital*
- 5:50 – 6:10 p.m.      **Oncolytic Virus Clinical Data**  
Brian D. Lichty, PhD – *McMaster University*
- 6:10 – 6:25 p.m.      **Preclinical Characterization of a Novel STING Agonist, MK-1454**  
Saso Cemerkski, PhD – *Merck Research Laboratories*
- 6:25 – 6:30 p.m.      **Closing Remarks**  
Samuel Rabkin, PhD – *Massachusetts General Hospital*

##### **Concurrent Session 108: Energizing Immune Cell Metabolism in Cancer**

*Maryland Ballroom*

*Co-Chairs:*

Susan M. Kaech, PhD – *Yale University*

Nicholas P. Restifo, MD – *National Cancer Institute*

- 5:05 – 5:25 p.m.      **Anti-Tumor T cells: You Are What You Eat**  
Susan M. Kaech, PhD – *Yale University*
- 5:25 – 5:45 p.m.      **Metabolic Control of T cell Epigenetics**  
Nicholas P. Restifo, MD – *National Cancer Institute*
- 5:45 – 6:05 p.m.      **Metabolic Changes in Tumor Microenvironment**  
Greg M. Delgoffe, PhD – *University of Pittsburgh*

- 6:05 – 6:20 p.m.      **Re-Educating Macrophage through Glutamine Metabolism-Mediated Metabolic and Epigenetic Reprogramming**  
Ping-Chih Ho, PhD – *University of Lausanne*
- 6:20 – 6:35 p.m.      **Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment**  
McLane Watson, BS – *University of Pittsburgh*
- 6:30 – 8 p.m.      **Poster Reception**  
*Prince George's Exhibition Hall DE*
- 8 – 9 p.m.      **Presidential Reception and Membership Business Meeting**  
*Cherry Blossom Ballroom*

### Saturday, November 11, 2017

- 7 – 8 a.m.      **Breakfast**  
*Maryland and Cherry Blossom Foyers*
- 7 a.m. – 6 p.m.      **Registration**  
*Cherry Blossom Foyer*
- 8 – 8:05 a.m.      **Organizer Welcome**  
Charles G. Drake, MD, PhD – *Columbia University Medical Center*

### **Update Session**

**Session 200: Cancer Immunotherapy Trials Network (CITN) Update**  
*Maryland Ballroom*

- 8:05 – 8:35 a.m.      **Cancer Immunotherapy Trials Network (CITN)**  
Martin A. Cheever, MD – *Fred Hutchinson Cancer Research Center*

### **Plenary Session**

**Session 201: Richard V. Smalley, MD Memorial Lectureship**  
*Maryland Ballroom*

- 8:35 – 8:40 a.m.      **Introduction**  
Lisa H. Butterfield, PhD – *University of Pittsburgh*
- 8:40 – 9:20 a.m.      **Activation of Innate and Adaptive Immunity as an *In Situ* Cancer Vaccine**  
Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*
- 9:20 – 9:25 a.m.      **Question & Answer**  
Paul M. Sondel, MD, PhD – *University of Wisconsin, Madison*

### **Plenary Session**

**Session 202: Mechanisms of Acquired Resistance to Immunotherapies**  
*Maryland Ballroom*

*Co-Chairs:*

Katerina Politi, PhD – *Yale School of Medicine*  
Antoni Ribas, MD, PhD – *University of California, Los Angeles*

- 9:25 – 9:30 a.m.      **Introduction**  
Katerina Politi, PhD – *Yale School of Medicine*
- 9:30 – 9:55 a.m.      **Acquired Resistance Checkpoint Inhibitors in Lung Cancer**  
Katerina Politi, PhD – *Yale School of Medicine*

9:55 – 10:20 a.m.	<b>Acquired Resistance to PD-1 Blockade in Melanoma</b> Antoni Ribas, MD, PhD – <i>University of California, Los Angeles</i>
10:20 – 10:45 a.m.	<b>Break</b> <i>Prince George's Exhibition Hall DE</i>
10:45 – 11:10 a.m.	<b>Acquired Resistance in Melanoma</b> Annette Paschen, MD – <i>University Hospital Essen</i>
11:10 – 11:25 a.m.	<b>Single cell RNA Sequencing Reveals Mechanisms of Merkel Cell Carcinoma Escape from Intense Pressure of T cell Immunotherapy</b> Kelly Paulson, PhD, MD - <i>Fred Hutchinson Cancer Research Center</i>
11:25 – 11:40 a.m.	<b>A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance</b> Jason Williams, BS - <i>University of Chicago</i>
11:40 – 11:55 a.m.	<b>Functional Correlation of Increased Tumor Intrinsic Glycolytic Activity with Resistance to Adoptive T cell Therapy</b> Weiyi Peng, PhD, MD - <i>The University of Texas MD Anderson Cancer Center</i>
11:55 a.m. – Noon	<b>Closing Remarks</b> Antoni Ribas, MD, PhD – <i>University of California, Los Angeles</i>

#### Late-Breaking Abstract Session

##### Session 203: Oral Abstract Presentations

*Maryland Ballroom*

Noon – 12:15 p.m.	<b>Preliminary Antitumor and Immunomodulatory Activity of BMS-986205, an Optimized Indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor, in Combination with Nivolumab in Patients with Advanced Cancers</b> Jason J. Luke, MD – <i>University of Chicago Medical Center</i>
12:15 – 12:30 p.m.	<b>The Transcription Factor Myb Enhances CD8+ T cell Stemness and Polyfunctionality to Promote Curative Antitumor Immunity</b> Sanjivan Gautam, PhD – <i>National Cancer Institute</i>
12:30 – 2 p.m.	<b>Lunch, Poster Viewing,* Exhibits</b> <i>Prince George's Exhibition Hall DE</i> <i>*Even Poster Number Authors Present</i>
12:45 – 1:45 p.m.	<b>Oral Poster Session</b> <i>Back of Prince George's Exhibition Hall DE</i>

#### Concurrent Sessions

##### Concurrent Session 204: Presidential Session

*Maryland Ballroom C*

*Chair: Lisa H. Butterfield, PhD – University of Pittsburgh*

2 – 2:05 p.m.	<b>Introduction</b> Lisa H. Butterfield, PhD – <i>University of Pittsburgh</i>
2:05 – 2:20 p.m.	<b>Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors</b> Vinod Balachandran, MD – <i>Memorial Sloan Kettering Cancer Center</i>

2:20 – 2:35 p.m.	<b>Neoadjuvant Nivolumab versus Combination Ipilimumab and Nivolumab followed by Adjuvant Nivolumab in Patients with Resectable Stage III and Oligometastatic Stage IV Melanoma: Preliminary Findings</b> Sangeetha M. Reddy, MD, MSc – <i>The University of Texas MD Anderson Cancer Center</i>
2:35 – 2:45 p.m.	<b>Expert Discussant</b> Charles Drake, MD, PhD – <i>Columbia University Medical Center</i>
2:45 – 3 p.m.	<b>Cross-Dressed Dendritic Cells Drive Anti-Tumor Immunity</b> Brendan MacNabb, BS – <i>The University of Chicago</i>
3 – 3:15 p.m.	<b>Metabolic Adaptations Establish Immunotherapy Resistance in Melanoma</b> Ashvin R. Jaiswal, DPharm, MS, PhD – <i>UT MD Anderson Cancer Center</i>
3:15 – 3:25 p.m.	<b>Expert Discussant</b> Susan M. Kaech, PhD – <i>Yale University</i>

#### Concurrent Session 205: Tumor Immunology 101 (Physician/Nurse/Pharmacist Track)

*Cherry Blossom Ballroom*

*Co-Chairs:*

Laura S. Wood, RN, MSN, OCN – *Cleveland Clinic Taussig Cancer Center*

Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*

2 – 2:05 p.m.	<b>Introduction</b> Laura S. Wood, RN, MSN, OCN – <i>Cleveland Clinic Taussig Cancer Center</i>
2:05 – 2:30 p.m.	<b>Immunology 101 for the Non-Immunologist</b> Yvonne Saenger, MD – <i>Columbia University Medical Center</i>
2:30 – 2:55 p.m.	<b>Basic Principles of Tumor Immunotherapy</b> Michael K. Wong, MD, PhD, FRCP – <i>MD Anderson Cancer Center</i>
2:55 – 3:20 p.m.	<b>Drug Classifications and Mechanisms of Action</b> Lisa Cordes, PharmD, BCACP, BCOP – <i>National Cancer Institute/National Institutes of Health</i>
3:20 – 3:25 p.m.	<b>Closing Remarks</b> Krista M. Rubin, MS, FNP-BC – <i>Massachusetts General Hospital</i>
3:25 – 3:40 p.m.	<b>Break</b>

#### Concurrent Session 206: Economics of Immunotherapies and Immunotherapy Combinations

*Maryland Ballroom C*

*Co-Chairs:*

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Bruce Levine, PhD – *Abramson Cancer Center*

3:25 – 3:27 p.m.	<b>Introduction</b> Michael B. Atkins, MD – <i>Georgetown Lombardi Comprehensive Cancer Center</i>
3:27 – 3:42 p.m.	<b>Report on Economics of Checkpoint Inhibitors in Melanoma</b> Ahmad Tarhini, MD, PhD – <i>University of Pittsburgh Cancer Institute</i>
3:42 – 3:57 p.m.	<b>Report on Economics of Adoptive Cell Therapy</b> Richard Maziarz, MD – <i>Oregon Health &amp; Science University</i>
3:57 – 4 p.m.	<b>Q&amp;A and Closing Remarks</b>

4 – 4:15 p.m. **Break**  
*Maryland Foyers*

**Concurrent Session 207: Clinical Trials: Novel Combinations**

*Room: Maryland Ballroom A*

- 3:30 – 3:45 p.m. **A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC)**  
Funda Meric-Bernstam, MD – *The University of Texas MD Anderson Cancer Center*
- 3:45 – 4 p.m. **ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC)**  
Leena Gandhi, MD, PhD – *NYU Langone Medical Center*
- 4 – 4:15 p.m. **OX40 T cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results**  
Anthony J. Olszanski, MD – *Fox Chase Cancer Center*
- 4:15 – 4:30 p.m. **Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab**  
Jose Saro, MD – *Roche Innovation Center Zurich*
- 4:30 – 4:45 p.m. **First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti-CSF-1 Receptor (Cabiralizumab) Plus Anti-PD-1 (Nivolumab), in Patients with Advanced Solid Tumors**  
Zev Wainberg, MD – *UCLA School of Medicine*
- 4:45 – 5 p.m. **TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patients**  
Cara Haymaker, PhD – *University of Texas MD Anderson Cancer Center*
- 5 – 5:15 p.m. **Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/ Metastatic Solid Tumors**  
Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*
- 5:15 – 5:30 p.m. **DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)**  
Douglas McNeel, MD, PhD – *University of Wisconsin*
- 5:30 – 5:45 p.m. **A Dendritic cell Targeting NY-ESO-1 Vaccine Significantly Augments Early and Durable Immune Responses in Melanoma Patients Pretreated with Human Flt-3 Ligand**  
Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Mount Sinai Medical Center*
- 5:45 – 6 p.m. **Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation**  
Jason Luke, MD – *University of Chicago Medical Center*



**Concurrent Session 208: Clinical Management** *(Physician/Nurse/Pharmacist Track)*
*Cherry Blossom Ballroom*
*Co-Chairs:*

Laura S. Wood, RN, MSN, OCN – *Cleveland Clinic Taussig Cancer Center*

Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*

3:40 – 3:45 p.m.	<b>Introduction</b> Laura S. Wood, RN, MSN, OCN - <i>Cleveland Clinic Taussig Cancer Center</i>
3:45 – 4:15 p.m.	<b>General Concepts of Toxicity Management</b> Michael Postow, MD – <i>Memorial Sloan Kettering Cancer Center</i>
4:15 – 4:35 p.m.	<b>Pharmacological Management of irAEs</b> Nathan Dahl, Pharm D, R.Ph – <i>Mayo Clinic</i>
4:35 – 5 p.m.	<b>Panel Discussion: Management of Complex Adverse Events</b> <i>Moderator:</i> Laura S. Wood, RN, MSN, OCN - <i>Cleveland Clinic Taussig Cancer Center</i> <i>Panelists:</i> Krista M. Rubin, MS, FNP-BC – <i>Massachusetts General Hospital</i> Nathan Dahl, Pharm D, R.Ph – <i>Mayo Clinic</i> Michael Postow, MD – <i>Memorial Sloan Kettering Cancer Center</i>
5 – 5:15 p.m.	<b>Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool</b> Krista Marcello, BA – <i>Clinical Care Options, LLC</i>
5:15 – 5:30 p.m.	<b>Audience Q&amp;A</b> <i>Moderator:</i> Krista M. Rubin, MS, FNP-BC – <i>Massachusetts General Hospital</i>

**Concurrent Session 209: Emerging Models & Imaging**
*Maryland Ballroom C*
*Co-Chairs:*

Daniel Thorek, PhD – *Johns Hopkins University School of Medicine*

Ronald N. Germain, MD, PhD – *National Institute of Allergy and Infectious Diseases, National Institute of Health*

4:15 – 4:20 p.m.	<b>Introduction</b> Ronald N. Germain, MD, PhD – <i>National Institute of Allergy and Infectious Diseases, National Institute of Health</i>
4:20 – 4:40 p.m.	<b>Imaging Immunity - Developing a Spatiotemporal Understanding of Host Defense and Tumor Immunity</b> Ronald N. Germain, MD, PhD – <i>National Institute of Allergy and Infectious Diseases, National Institute of Health</i>
4:40 – 5 p.m.	<b>Molecular Imaging of Checkpoint Blockade</b> Daniel Thorek, PhD – <i>Johns Hopkins University School of Medicine</i>
5:05 – 5:20 p.m.	<b>Multiplex Three-Dimensional Optical Mapping of Tumor Immune Microenvironment</b> Steve Seung-Young Lee, PhD – <i>University of Chicago</i>
5:20 – 5:35 p.m.	<b>Combining Immunophenomics with a Gene Expression Panel for Improved Prostate Cancer Recurrence Prediction</b> Nathalie Harder, PhD – <i>Definiens AG</i>
5:35 – 5:40 p.m.	<b>Closing Remarks</b> Daniel Thorek, PhD – <i>Johns Hopkins University School of Medicine</i>



### Award Ceremony

Maryland Ballroom C

- |                   |   |
|-------------------|---|
| 6 – 6:30 p.m.     | <b>Award Ceremony</b><br>Lisa H. Butterfield, PhD – <i>University of Pittsburgh</i> |
| 6:30 – 8 p.m.     | <b>Poster Reception</b><br><i>Prince George's Exhibition Hall DE</i>                |
| 8:30 – 11:30 p.m. | <b>The CheckPoints Party</b><br><i>Maryland Ballroom</i>                            |

### Sunday, November 12, 2017

- |               |  |
|---------------|--|
| 7 – 8 a.m.    | <b>Breakfast</b><br><i>Cherry Blossom Foyer</i>  |
| 7 – 10 a.m.   | <b>Registration</b><br><i>Cherry Blossom Foyer</i>   |
| 8 – 8:05 a.m. | <b>Organizer Welcome</b><br>Marcela V. Maus, MD, PhD – <i>Massachusetts General Hospital</i> |

### Plenary Session

#### **Session 300: Genetically Modified Cell Therapy**

*Organized in collaboration with the American Society for Blood and Marrow Transplantation (ASBMT)*

*Cherry Blossom Ballroom*

*Co-Chairs:*

Marcela V. Maus, MD, PhD – *Massachusetts General Hospital*

Helen E. Heslop, MD – *Baylor College of Medicine*

Carl H. June, MD – *University of Pennsylvania*

- |                  |   |
|------------------|---|
| 8:05 – 8:30 a.m. | <b>Gene Edited CAR T cells</b><br>Martin Pule, PhD – <i>University College London</i>   |
| 8:30 – 8:55 a.m. | <b>Updates in CAR T cells</b><br>Crystal L. Mackall, MD – <i>Stanford University</i>  |
| 8:55 – 9:20 a.m. | <b>Genetically Modified T Cells for Solid Tumors</b><br>Stephen M. Gottschalk, MD – <i>St. Jude Children's Research Hospital</i>  |
| 9:20 – 9:45 a.m. | <b>Late-Breaking: CD19 CAR Enter the Mainstream</b><br>Jennifer Brogdon – <i>Novartis Institute of Biomedical Research</i>  |
| 9:45 – 10 a.m.   | <b>Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cells</b><br>Angela Boroughs, BS – <i>Massachusetts General Hospital, Harvard University</i>           |
| 10 – 10:15 a.m.  | <b>Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T cells</b><br>Margot Pont, PhD – <i>Fred Hutchinson Cancer Research Center</i> |

## Hot Topic Symposium

### Session 301: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?

*Organized in collaboration with Stand Up To Cancer (SU2C)*

*Cherry Blossom Ballroom*

*Co-Chairs:*

Howard Kaufman, MD, FACS – *Replimune Group Inc.*

Herbert Levine, PhD – *Rice University*

10:30 – 10:35 a.m.	<b>Welcome and Introductions</b> Howard Kaufman, MD, FACS – <i>Replimune Group, Inc.</i>
10:35 – 10:55 a.m.	<b>Overview of the Immunotherapy Field</b> Francesco M. Marincola, MD – <i>AbbVie Inc.</i>
10:55 – 11:15 a.m.	<b>Emerging Topics</b> Thomas F. Gajewski, MD, PhD – <i>University of Chicago</i>
11:15 – 11:35 a.m.	<b>Challenges in Clinical Development</b> Michael Postow, MD – <i>Memorial Sloan Kettering Cancer Center</i>
11:35 – 11:55 a.m.	<b>Systems of Biology Modeling of the Immune System</b> Doron Levy, PhD – <i>University of Maryland</i>
11:55 a.m. – 12:15 p.m.	<b>T cell Repertoire</b> Curtis Callan, PhD – <i>Princeton University</i>
12:15 – 12:35 p.m.	<b>Modeling the Fitness Costs of Neoantigens</b> Benjamin Greenbaum, PhD – <i>The Tisch Cancer Institute</i>
12:35 – 1 p.m.	<b>Panel Discussion</b> Moderators: Howard Kaufman, MD, FACS – <i>Replimune Group, Inc.</i> Herbert Levine, PhD – <i>Rice University</i>